

[Skip to main navigation](#)

[Soleno](#)

- [Company](#)
 - [Management](#)
 - [Board](#)
 - [Advisors](#)
 - [Careers](#)
- [Product Candidate](#)
 - [DCCR](#)
 - [Mode of Action](#)
 - [Clinical Study \(PC025\)](#)
 - [Clinical Studies](#)
- [For Patients](#)
 - [Prader-willi Syndrome](#)
- [Capnia Products](#)
 - [CoSense[®] ETCO Monitor](#)
 - [Overview](#)
 - [Technology](#)
 - [Clinical References](#)
 - [Other Applications](#)
 - [Product Resources](#)
- [Investors](#)
 - [Investor Overview](#)
 - [Press Releases](#)
 - [Events & Presentations](#)
 - [Event Calendar](#)
 - [Presentations](#)
 - [Corporate Governance](#)
 - [Governance Highlights](#)
 - [Management](#)
 - [Board of Directors](#)
 - [Committee Composition](#)
 - [Contact The Board](#)
 - [Financials & Filings](#)
 - [SEC Filings](#)
 - [Annual Reports](#)
 - [Quarterly Results](#)
 - [Fundamentals](#)
 - [Stock Information](#)
 - [Stock Quote](#)
 - [Stock Chart](#)
 - [Historical Price Lookup](#)
 - [Investment Calculator](#)
 - [Analyst Coverage](#)
- [Contact us](#)

Investors

- [Investor Overview](#)
- [Press Releases](#)
- [Events & Presentations](#)
- [Corporate Governance](#)
- [Financials & Filings](#)
- [Stock Information](#)

Investor Overview

Corporate Profile

Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017. Soleno, through its wholly owned subsidiary, Capnia, Inc., continues to market Capnia's innovative medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. It is expected that this product will be monetized and will not be a focus for the company in the long term.

Featured Report

[2016 10-K](#)

Stock Performance

[3 mo.](#) [6 mo.](#) [1 yr.](#)

Change

Volume

52 Week High

52 Week Low

Mar 19, 2018 4:34 AM EDT

Copyright Nasdaq. Minimum 15 minutes delayed.

Recent News

[Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome](#)
February 20, 2018

[Soleno Therapeutics Announces \\$15 Million Private Placement](#) December 12, 2017

[Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology](#) December 8, 2017

[More News](#)

Upcoming Events

There are currently no events to display.

[More Events](#)

[Print Page](#) [RSS Feeds](#) [Email Alerts](#) [IR Contacts](#)

Logo

Developing novel therapeutics for the treatment of rare diseases.

Pages

- [Company](#)
 - [Management](#)
 - [Boards](#)
 - [Advisors](#)
 - [Careers](#)
- [Product Candidate](#)
 - [DCCR](#)
 - [Mode of Action](#)
 - [Clinical Study \(PC025\)](#)
 - [Clinical Studies](#)
- [For Patients](#)
 - [Prader-willi Syndrome](#)
- [Capnia Products](#)
 - [CoSense[®] ETCO Monitor](#)
- [Investors](#)
 - [Investor Overview](#)
 - [Press Releases](#)
 - [Events & Presentations](#)
 - [Corporate Governance](#)
 - [Financials & Filings](#)
 - [Stock Information](#)
- [Contact us](#)

News and Events

[Solen Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome](#)

[Solen Therapeutics Announces \\$15 Million Private Placement](#)

Contact Us

- 1235 Radio Road
- Suite 110
- Redwood City, CA 94065

- Tel: (650) 213-8444
- Email: info@solen.life

Solen Therapeutics, Inc. © 2017 | All Rights Reserved

- [Terms of Use](#)
- [Privacy Statement](#)